Head-to-head · WeighScore
Prime Health vs Remedy Meds
By GLP-1 ScorecardUpdated
Score comparison
Prime Health has the higher recorded score — 59.4/100 to 51.8/100.
Prime Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Prime Health (joinprimehealth.com) is a LegitScript-certified GLP-1 telehealth platform offering compounded semaglutide and tirzepatide for weight loss.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Prime Health | Remedy Meds |
|---|---|---|
| WeighScore | 59.4/100 | 51.8/100 |
| Grade | C | C |
| Site position | #391 | #523 |
| Semaglutide | $299/mo (compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | $399/mo (compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #391 · C
Strengths
- LegitScript-certified platform
- Flat pricing that does not rise as dosage increases
- Bundle includes medication, labs, shipping, and unlimited clinician access
- Money-back guarantee of at least 10% body-weight loss in 4 months
- Fast 24-hour prescription review and 5-7 day delivery
What to consider
- Compounded medications only; no FDA-approved brand options listed
- Not available in Louisiana
- Care delivered through third-party clinician groups, not in-house
- Named compounding pharmacy not disclosed
- No insurance accepted
Site position #523 · C
FDAWarning letter issued to Remedy Meds in September 2025. See the FDA warning-letter database.
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
What to consider
- Limited public information on program details
- FDA issued Remedy Meds a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.